CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo …